Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nexell Therapeutics

This article was originally published in The Gray Sheet

Executive Summary

Cell therapy company completes a $63 mil. private placement with institutional investors. Irvine, California-based Nexell will use the proceeds to retire about $34 mil. in convertible subordinated debentures held by shareholder Baxter, as well as for "general corporate purposes." Nexell's Isolex 300i gained FDA approval in July for the selection of hematopoietic stem cells and the removal of tumor cells from autologous peripheral blood grafts used to restore cancer patients' immune and blood-forming systems following high dose chemotherapy (1"The Gray Sheet" July 12, p. 11). Lehman Brothers served as placement agent for the transaction

You may also be interested in...

Nexell Planning To Seek Labeling Expansion For Isolex 300i In 2001

Nexell Therapeutics plans to file two premarket approval applications in the second half of 2001 to expand labeling for its Isolex 300i magnetic cell selection system, which gained FDA approval July 6.

UK Grants First Worldwide Authorization For PfIzer/BioNTech COVID-19 Vaccine

The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.

Wockhardt Preps To Deliver 100M Doses Of AZ Vaccine

As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts